(0.32%) 5 116.14 points
(0.32%) 38 363 points
(0.35%) 15 983 points
(-0.92%) $83.08
(5.56%) $2.03
(0.35%) $2 355.30
(0.41%) $27.65
(4.00%) $958.95
(-0.25%) $0.932
(-0.41%) $10.98
(-0.56%) $0.796
(1.69%) $93.43
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 12.06%
@ $42.63
発行日: 30 4月 2024 @ 01:03
リターン: 0.05%
前回のシグナル: 4月 29 - 23:52
前回のシグナル:
リターン: 0.32 %
Live Chart Being Loaded With Signals
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases...
Stats | |
---|---|
本日の出来高 | 275 391 |
平均出来高 | 1.40M |
時価総額 | 7.74B |
EPS | $-0.760 ( 2024-03-27 ) |
次の収益日 | ( $-0.610 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -15.97 |
ATR14 | $0.300 (0.70%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-01 | Coles N Anthony | Sell | 50 000 | Stock Option (Right to Buy) |
2024-04-01 | Coles N Anthony | Buy | 50 000 | Common Stock |
2024-04-01 | Coles N Anthony | Sell | 50 000 | Common Stock |
2024-03-04 | Coles N Anthony | Sell | 50 000 | Stock Option (Right to Buy) |
2024-03-04 | Coles N Anthony | Buy | 50 000 | Common Stock |
INSIDER POWER |
---|
83.46 |
Last 99 transactions |
Buy: 19 058 481 | Sell: 1 552 762 |
ボリューム 相関
Cerevel Therapeutics 相関
10 最も負の相関 | |
---|---|
SBBP | -0.894 |
THMA | -0.882 |
GMII | -0.876 |
ALGM | -0.854 |
DTEA | -0.848 |
CFV | -0.843 |
VEDU | -0.832 |
PETV | -0.83 |
NRDS | -0.821 |
JCTCF | -0.815 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Cerevel Therapeutics 相関 - 通貨/商品
Cerevel Therapeutics 財務諸表
Annual | 2023 |
収益: | $0 |
総利益: | $-5.63M (0.00 %) |
EPS: | $-2.67 |
FY | 2023 |
収益: | $0 |
総利益: | $-5.63M (0.00 %) |
EPS: | $-2.67 |
FY | 2022 |
収益: | $0 |
総利益: | $-4.90M (0.00 %) |
EPS: | $-2.32 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.650 |
Financial Reports:
No articles found.
Cerevel Therapeutics
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist, which is in Phase 2a clinical trial to treat dementia-related apathy; CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I clinical trial for the treatment of substance use disorder; CVL-354, a selective kappa-opioid receptor antagonist to treat major depressive disorder and substance use disorder; and CVL-047, selective PDE4 inhibitor for the treatment of major depressive disorder and substance use disorder. It is also involved in the development of an M4 agonist program for the treatment of psychosis and related indications; and an LRRK2 inhibitor program to address disease progression in Parkinson's. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。